This is the authors' abstract. We don't add key points for this paper.
Ovarian cancer is notorious for peritoneal dissemination and chemoresistance caused by its REDOX homeostasis. Ruthenium-based photosensitizers that destroy the REDOX homeostasis in tumor cells by oxidizing NADH and generating ROS can respond only to blue-green light with poor tissue penetration, thus limiting further clinical applications. Thus, a Ru-based nanoplatform (MR@Au) integrating Mn structural sites and in situ -grown single-atom Au clusters was developed to overcome the limited tissue penetration depth of light sources in the photocatalytic process mediated by Ru-based photosensitizers. This system is engineered for NIR-II photoacoustic imaging-guided redox homeostasis disruption and nonhigh- Z -element-dependent radiosensitization strategy. The localized surface plasmon resonance (LSPR) effect induced by monodispersed Au single-atom clusters endows MR@Au with full-spectrum absorption spanning 500–800 nm, enabling efficient responsiveness to NIR irradiation. The discrete atomic distribution of Au clusters facilitates rapid biodegradation and renal clearance─a critical advantage absent in conventional high-Z-element-based radiosensitizers. MR@Au, engineered to enable deep-tissue photodynamic activation and ensure rapid metabolic clearance, proposes a clinically translatable radiosensitization strategy for drug-resistant malignancies while it redefines the design paradigm for small-molecule photosensitizer-based therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: